The study was a randomized, placebo-controlled comparison of the effects of daily treatment with fenofibrate 160 mg, ezetimibe-simvastatin 10/20 mg, ezetimibe-simvastatin 10/20 mg plus fenofibrate 160 ...

STOCKHOLM, Sweden — Adding fenofibrate to a statin was associated with an 11% lower risk of diabetic retinopathy progression in patients with type 2 diabetes, new study data show. The drug combination ...

NEW ORLEANS, November 8, 2004 – Results from a new study showed that coadministration of ZETIA® (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density ...

Use of the cholesterol-lowering drug fenofibrate had a modest but statistically significant association with reduced risk of vision-threatening diabetic retinopathy (VTDR), according to results of a ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. FENOFIBRATE VIATRIS contains the active ingredient fenofibrate.

Please provide your email address to receive an email when new articles are posted on . Adults taking oral fenofibrate had a 27% reduction in diabetic eye disease progression over 4 years. Fenofibrate ...

Parsippany, NJ (October 15, 2004) – The results of a new study, published in the September 2004 issue of Clinical Pharmacokinetics, showed that no significant drug-drug interaction occurred when ...

Fenofibrate as an adjunct to statins was associated with lower risks for all-cause mortality and cardiovascular disease among individuals with type 2 diabetes. Fenofibrate as an adjunct to statin ...

CLEVELAND — Fenofibrate, patented in 1969 and in medical use since 1975, is well-established as a cholesterol-lowering treatment. However, University Hospitals scientists believe it may also have the ...

The resurgence of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to renewed efforts to find effective antivirals, ...